Human microbiome

Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies

Retrieved on: 
Tuesday, October 6, 2020
Health sciences, Branches of biology, Microbiology, Environmental microbiology, Bacteriology, Microbiomes, Medicinal chemistry, Therapy, Human microbiome

Horizons Ventures led the Series A financing, joined by existing investors Venrock and Altitude, and additional new investors Seventure Partners/Health for Life Capital.

Key Points: 
  • Horizons Ventures led the Series A financing, joined by existing investors Venrock and Altitude, and additional new investors Seventure Partners/Health for Life Capital.
  • "The Federation Bio team has already developed critical platform capabilities and generated strong pre-clinical data.
  • "Federation Bio's completely novel approach to microbial therapy creates tremendous potential for a wide range of effective, broadly applicable therapies," said Dr. Conley.
  • Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role.

Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients

Retrieved on: 
Wednesday, September 30, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, Branches of biology, Medical specialties, Bacteriology, Microbiomes, Environmental microbiology, Microbiology, Digestive system, Clostridioides difficile infection, Clostridioides difficile, Human microbiome, Microbiota, Colonization resistance, VE303, Vedanta Biosciences

View the full release here: https://www.businesswire.com/news/home/20200930005199/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200930005199/en/
    Vedanta Biosciences announced it has been awarded up to $76.9 million including $7.4 million upfront from the Biomedical Advanced Research and Development Authority (BARDA) to advance clinical development of VE303 for high-risk Clostridioides difficile infection (CDI).
  • A previous Phase 1a/1b study demonstrated rapid, durable, dose-dependent colonization and accelerated restoration of gut microbiota in healthy volunteers who were pretreated with antibiotics.
  • VE303 consists of a defined consortium of live bacteria designed to restore colonization resistance against gut pathogens, including C. difficile.
  • Vedanta Biosciences received a $5.4 million research grant from CARB-X in 2017 and a grant from BARDA in 2020 to support clinical studies of VE303.

DuPont Human Microbiome Venture and Procter & Gamble Enter Research Collaboration in Next Generation Probiotics

Retrieved on: 
Monday, September 21, 2020
Branches of biology, Microbiomes, Microscopy, Bacteriology, Microbiology, Environmental microbiology, DuPont, DuPont, Human microbiome, Cision

COPENHAGEN, Denmark, Sept. 21, 2020 /PRNewswire-PRWeb/ --The DuPont Human Microbiome Venture today announced a research partnership with The Procter & Gamble Company (P&G), focusing on the discovery and development of innovative next generation probiotics (NGPs) for human health.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 21, 2020 /PRNewswire-PRWeb/ --The DuPont Human Microbiome Venture today announced a research partnership with The Procter & Gamble Company (P&G), focusing on the discovery and development of innovative next generation probiotics (NGPs) for human health.
  • Over the past years, both P&G and DuPont have conducted extensive research on human commensals to help address metabolic health issues in humans.
  • "It's an exciting opportunity to partner with P&G to jointly develop the next generation of microbe-based products.
  • DuPont, the DuPont Oval Logo, and all trademarks and service marks denoted with , SM or are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Biocodex Microbiota Foundation U.S. Research Grant Supports Ground-Breaking Research on Gut Microbiota, Now Accepting 2020 Applicants

Retrieved on: 
Tuesday, September 15, 2020
Branches of biology, Microbiology, Microbiomes, Microscopy, Bacteriology, Bacteria, Environmental microbiology, Microbiota, Human microbiome

Biocodex Microbiota Foundation's annual call for grant applications is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies.

Key Points: 
  • Biocodex Microbiota Foundation's annual call for grant applications is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies.
  • To learn more information about Biocodex Microbiota Foundation and the 2020 U.S. grant program click here .
  • The Biocodex Microbiota Foundation's mission is to support research into microbiota and its interaction with various pathologies.
  • The Biocodex Microbiota Foundation supports both foundational and applied research, and projects are selected annually by a committee of independent scientists.

Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

Retrieved on: 
Friday, September 11, 2020
Biotechnology, Pharmaceutical, General Health, Health, FDA, Infectious diseases, Clinical trials, Other Health, Branches of biology, Health, Feces, Fecal microbiota transplant, Microbiology, Breakthrough therapy, Food and Drug Administration, Human microbiome, David Berry, SER-109, C. difficile Infection (CDI) and Current Treatments, Seres Therapeutics

After obtaining highly statistically significant topline Phase 3 ECOSPOR III SER-109 study results in recurrent CDI, Seres requested a Breakthrough Therapy Designation meeting with the FDA.

Key Points: 
  • After obtaining highly statistically significant topline Phase 3 ECOSPOR III SER-109 study results in recurrent CDI, Seres requested a Breakthrough Therapy Designation meeting with the FDA.
  • Seres is taking various measures to expedite open-label study enrollment, including increasing the number of SER-109 clinical study sites across the U.S. and Canada.
  • Seres also anticipates that the quarantine of material used for unapproved Fecal Microbiota Transplantation (FMT) by a national provider will accelerate SER-109 open-label study enrollment.
  • Seres SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA.

Worldwide Human Microbiome Immunology Therapeutics Industry to 2025 - The US Dominates the Global Market Landscape

Retrieved on: 
Friday, September 4, 2020
Branches of biology, Microbiology, Microbiomes, Microscopy, Bacteriology, Environmental microbiology, Bacteria, Human microbiome, Microbiota, Pharmacomicrobiomics

DUBLIN, Sept. 3, 2020 /PRNewswire/ -- The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 3, 2020 /PRNewswire/ -- The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology.
  • The Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025 report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology.
  • The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge
    Global Human Microbiome Immunology Therapeutics Market: >US$ 1 Billion by 2025
    US Dominates Global Market Landscape: >60% Market Share
    Global Microbiome Modulator Drugs in Clinical Pipeline: >80 Drug in Trials
    Clinical Trial Studies Related to Fecal Microbiota Transplant: > 250 Clinical Trials

Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insights to 2025 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 1, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Microscopy, Bacteriology, Microbiology, Microbiomes, Environmental microbiology, Bacteria, Microbiota, Human microbiome, Pharmacomicrobiomics, Human Microbiome Project

The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology.
  • microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time.
  • The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

Human Microbiome Therapeutics Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Growing Prevalence of Chronic Diseases to Boost the Market Growth | Technavio

Retrieved on: 
Monday, August 31, 2020
Health, Pharmaceutical, Branches of biology, Microscopy, Bacteriology, Microbiology, Microbiomes, Environmental microbiology, Bacteria, Microbiota, Human microbiome

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
  • The growing prevalence of chronic diseases is one of the major factors driving the market.
  • Human Microbiome Therapeutics Market 2020-2024: Segmentation
    Human Microbiome Therapeutics Market is segmented as below:

MaaT Pharma Announces Initiation of New Collection and Manufacturing Campaign for its Microbiome Biotherapeutic Product Portfolio

Retrieved on: 
Thursday, August 20, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical trials, Branches of biology, Microbiomes, Microscopy, Bacteriology, Microbiology, Environmental microbiology, Bacteria, Human microbiome, Compounding, Microbiota

Based on this ANSM decision, collection of fecal microbiota can resume for all uses (bulk compounding, hospital compounding and medicine production), following certain additional guidelines.

Key Points: 
  • Based on this ANSM decision, collection of fecal microbiota can resume for all uses (bulk compounding, hospital compounding and medicine production), following certain additional guidelines.
  • MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases.
  • Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome.
  • MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.

The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases

Retrieved on: 
Monday, August 17, 2020
Branches of biology, Microbiomes, Microscopy, Microbiology, Bacteriology, Bacteria, Environmental microbiology, Microbiota, Human microbiome, Human Microbiome Project, Pharmacomicrobiomics

MONTREAL, Aug. 17, 2020 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation , an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is calling for grant proposals from innovative researchers at Canadian institutions.

Key Points: 
  • MONTREAL, Aug. 17, 2020 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation , an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is calling for grant proposals from innovative researchers at Canadian institutions.
  • The Biocodex Microbiota Foundations annual call for projects is part of a multi-year research initiative to further the understanding of the human microbiome.
  • The Biocodex Microbiota Foundation is a non-profit, general interest organization that supports research into microbiota and their interaction with various pathologies.
  • Projects investigating the implication of microbiota in human health are selected annually by committees of independent international scientists.